Lexicon Pharmaceuticals (LXRX) Amortization of Deferred Charges (2014 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Amortization of Deferred Charges of $681000.0 for Q1 2026, up 69.83% year-over-year from $401000.0 in Q1 2025, and up 37.58% quarter-over-quarter from $495000.0 in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Amortization of Deferred Charges for 13 consecutive years, with $681000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 69.83% year-over-year to $681000.0; the TTM figure through Mar 2026 stood at $2.0 million (up 14.52% YoY), while the FY2025 annual figure was $1.7 million, down 7.86% from the prior year.
- Amortization of Deferred Charges climbed to $681000.0 in Q1 2026 per LXRX's latest filing, from $495000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $681000.0 in Q1 2026 and bottomed at $25000.0 in Q1 2022.
- Historically, Amortization of Deferred Charges has averaged $396529.4 across 5 years, with a median of $402000.0 in 2024.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges surged 4212.5% — and 2024, when it plunged 35.11%.
- Lexicon Pharmaceuticals' Amortization of Deferred Charges stood at $345000.0 in 2022, then surged by 79.13% to $618000.0 in 2023, then slumped by 35.11% to $401000.0 in 2024, then climbed by 23.44% to $495000.0 in 2025, then surged by 37.58% to $681000.0 in 2026.
- Business Quant data shows LXRX's Amortization of Deferred Charges at $681000.0 in Q1 2026, $495000.0 in Q4 2025, and $402000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 532,000.00 |
| Mar 31, 2026 | 681,000.00 |
| Dec 31, 2025 | 495,000.00 |
| Sep 30, 2025 | 402,000.00 |
| Jun 30, 2025 | 402,000.00 |
| Mar 31, 2025 | 401,000.00 |
| Dec 31, 2024 | 401,000.00 |
| Sep 30, 2024 | 402,000.00 |
| Jun 30, 2024 | 525,000.00 |
| Mar 31, 2024 | 517,000.00 |
| Dec 31, 2023 | 618,000.00 |
| Sep 30, 2023 | 618,000.00 |
| Jun 30, 2023 | 273,000.00 |
| Mar 31, 2023 | 265,000.00 |
| Dec 31, 2022 | 345,000.00 |
| Sep 30, 2022 | 217,000.00 |
| Jun 30, 2022 | 154,000.00 |
| Mar 31, 2022 | 25,000.00 |
| Dec 31, 2021 | 8,000.00 |
| Sep 30, 2021 | 17,000.00 |